Drug name - Mounjaro

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(8 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(8 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

Market Authorisation Date: 13 May, 2022

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
5MG/0.5ML (5MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
7.5MG/0.5ML (7.5MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
10MG/0.5ML (10MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
12.5MG/0.5ML (12.5MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.5ML (15MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.